Zhejiang CONBA Pharmaceutical (600572) Fundamentals 2026 — P/E 22.5x, Revenue Analysis | SniperIQ
Zhejiang CONBA Pharmaceutical (600572) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥10.9B, trading at ¥4.30 on the SHH. This SniperIQ fundamentals page covers Zhejiang CONBA Pharmaceutical's valuation (P/E 22.5x, P/B 1.5x), profitability (net margin 7.2%), revenue (¥6.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang CONBA Pharmaceutical's market cap?
Zhejiang CONBA Pharmaceutical (600572) has a market capitalization of approximately ¥10.9B, trading at ¥4.30 on the SHH. Market cap moves with the live share price.
What is Zhejiang CONBA Pharmaceutical's P/E ratio?
Zhejiang CONBA Pharmaceutical's trailing twelve-month P/E ratio is 22.5x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang CONBA Pharmaceutical?
Zhejiang CONBA Pharmaceutical runs a net profit margin of 7.2%, a gross margin of 53.8%, and an operating margin of 8.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang CONBA Pharmaceutical generate?
Zhejiang CONBA Pharmaceutical reported revenue of ¥6.5B for fiscal year 2025, with net income of ¥474M and earnings per share (EPS) of 0.19. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang CONBA Pharmaceutical pay a dividend?
Zhejiang CONBA Pharmaceutical offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang CONBA Pharmaceutical financially healthy?
Zhejiang CONBA Pharmaceutical carries a debt-to-equity ratio of 0.05x and a current ratio of 1.98x, with a market beta of 0.23. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang CONBA Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang CONBA Pharmaceutical (600572) the key facts are: market cap ¥10.9B, P/E 22.5x, revenue ¥6.5B, 52-week range 3.77-5.17. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang CONBA Pharmaceutical's full fundamentals live
Get Zhejiang CONBA Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.